Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | TNF | P01375 | 2/20 | 0.45 |
| ▸ | TLR2 | O60603 | 3/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | DGKA | P23743 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4951870 | 0.93 | KMT2A (0.51) | KMT2AEPHX2 | |
| SCHEMBL27984222 | 0.92 | KMT2A (0.54) | KMT2ATNFTLR2EPHX2DGKA | |
| SCHEMBL16360194 | 0.92 | KMT2A (0.54) | KMT2ATNFTLR2EPHX2DGKA | |
| Hydrochloric Acid SCHEMBL28086829 | 0.91 | KMT2A (0.53) | KMT2ATNFTLR2EPHX2DGKA | |
| SCHEMBL14612149 | 0.91 | KMT2A (0.52) | KMT2ATNFTLR2EPHX2DGKA | |
| SCHEMBL388244 | 0.89 | KMT2A (0.58) | KMT2ALTA4HEPHX2 | |
| SCHEMBL10071038 | 0.87 | KMT2A (0.50) | KMT2ATNFTLR2EPHX2KDM4E | |
| SCHEMBL14759878 | 0.85 | KMT2A (0.60) | KMT2ATNFEPHX2 | |
| SCHEMBL307643 | 0.85 | KMT2A (0.57) | KMT2AEPHX2 | |
| SCHEMBL17249661 | 0.82 | KMT2A (0.50) | KMT2ATLR2EPHX2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1968714-B | Lipid, lipid complex and application thereof | SILENCE THERAPEUTICS AG | 2013-10-16 | — | — | CN | disclosed |
| CN-101287497-B | Lipid complexes coated with peg and their use | SILENCE THERAPEUTICS AG | 2013-03-06 | — | — | CN | disclosed |
| CN-102940891-A | Lipids, lipid complexes and use thereof | ATUGEN AG | 2013-02-27 | — | — | CN | disclosed |
| US-20080274116-A1 | Lipids, Lipid Complexes and Use Thereof | SILENCE THERAPEUTICS AG (DE) | 2008-11-06 | — | — | US | disclosed |
| CN-101287497-A | Lipid complexes coated with peg and their use | SILENCE THERAPEUTICS AG (DE) | 2008-10-15 | — | — | CN | disclosed |
| CN-1968714-A | Lipid, lipid complex and application thereof | ATUGEN AG (DE) | 2007-05-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080274116-A1 | Lipids, Lipid Complexes and Use Thereof | MGLL, LIPA, SGMS1 | KMT2A 693/4885TNF 2995/4885TLR2 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.